| scholarly article | Q13442814 |
| P2093 | author name string | B I Eisenstein | |
| W J Martone | |||
| B Donfrid | |||
| P Bernardo | |||
| P E Pertel | |||
| A S Link | |||
| E J A Biermann | |||
| P2860 | cites work | Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis | Q28757559 |
| Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 | Q33877838 | ||
| In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains | Q33979251 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes | Q34718540 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains | Q35023234 | ||
| Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria | Q35759049 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. | Q36231682 | ||
| In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin | Q36625774 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains | Q37156698 | ||
| Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus | Q38898667 | ||
| Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin | Q40275617 | ||
| Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates | Q40902642 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| Linezolid resistance in clinical isolates of Staphylococcus aureus | Q44257306 | ||
| Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) | Q44429058 | ||
| Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. | Q44466641 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals | Q46524907 | ||
| Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). | Q46722690 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations | Q79493278 | ||
| Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005) | Q79616255 | ||
| Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004) | Q80042884 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy | Q83863899 | ||
| P433 | issue | 3 | |
| P921 | main subject | vancomycin | Q424027 |
| P304 | page(s) | 368-375 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas | |
| P478 | volume | 63 |
| Q38258105 | Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients |
| Q37900838 | Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin |
| Q38115356 | Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on. |
| Q35628618 | Cutaneous infections and infestations: new therapies |
| Q44279637 | Daptomycin in complicated skin and soft tissue infections |
| Q37637758 | Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis |
| Q26752922 | Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections |
| Q37693931 | Daptomycin: pharmacology and clinical use. |
| Q28070326 | Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis |
| Q27000445 | Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials |
| Q89821699 | Efficacy and safety of daptomycin: systematic review and meta-analysis |
| Q24234864 | Interventions for cellulitis and erysipelas |
| Q37995865 | Medical management of diabetic foot infections |
| Q42544277 | Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design |
| Q46024308 | Neutropenia associated with prolonged daptomycin use. |
| Q41692440 | Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. |
| Q49397138 | Quaternary ammonium-induced multidrug tolerant Streptococcus mutans persisters elevate cariogenic virulence in vitro |
| Q52580415 | Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy. |
| Q36243256 | Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. |
| Q33834856 | The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. |
Search more.